GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 1,430 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,430 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20. Following the completion of the transaction, the chief financial officer now owns 26,770 shares of the company’s stock, valued at $2,035,590.80. This represents a 5.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total value of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total value of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $18,248.40.

GeneDx Stock Up 8.3 %

GeneDx stock opened at $97.04 on Wednesday. The company’s 50-day moving average price is $77.21 and its two-hundred day moving average price is $52.15. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of -31.20 and a beta of 2.02. GeneDx Holdings Corp. has a 52 week low of $2.80 and a 52 week high of $98.87. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. During the same quarter last year, the business posted ($0.82) earnings per share. The company’s quarterly revenue was up 44.3% on a year-over-year basis. On average, analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Several hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its position in GeneDx by 617.3% during the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company’s stock valued at $2,214,000 after purchasing an additional 44,889 shares during the last quarter. Principal Financial Group Inc. acquired a new position in shares of GeneDx during the 3rd quarter valued at about $604,000. Franklin Resources Inc. bought a new stake in GeneDx during the third quarter worth approximately $301,000. Tidal Investments LLC acquired a new position in GeneDx during the third quarter valued at approximately $514,000. Finally, Barclays PLC raised its position in shares of GeneDx by 346.3% in the third quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after purchasing an additional 14,681 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on WGS. The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Craig Hallum lifted their target price on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. TD Cowen boosted their price target on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.